FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Autoimmune Diseases topics
Immune Diseases
Autoimmune Disease
Autoimmune Diseases
Immune Disease
Autoimmune
Rheumatoid Arthritis
Antibodies
Proliferative
Nucleotide
Antagonist
Infectious Diseases
Inflammatory Disease
Infectious Disease
Infectious
Multiple Sclerosis

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Autoimmune Diseases patents



      
           
This page is updated frequently with new Autoimmune Diseases-related patent applications. Subscribe to the Autoimmune Diseases RSS feed to automatically get the update: related Autoimmune RSS feeds. RSS updates for this page: Autoimmune Diseases RSS RSS


Date/App# patent app List of recent Autoimmune Diseases-related patents
08/14/14
20140228349
 5,7-substituted-imidazo[1,2-c]pyrimidines patent thumbnailnew patent 5,7-substituted-imidazo[1,2-c]pyrimidines
Compounds of formula i: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which r1, r2, r3, r4, r5, r6, x1 and x2 have the meanings given in the specification, are inhibitors of one or more jak kinases and are useful in the treatment of autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.. .
08/14/14
20140228313
 Methods and compositions for preventing and treating a disease related to glycan dysregulation patent thumbnailnew patent Methods and compositions for preventing and treating a disease related to glycan dysregulation
Contemplated compositions and methods are directed to prevent and/or treat various autoimmune diseases that are typically associated with glycan dysregulation, and especially autoimmune demyelinating diseases. Further especially contemplated aspects include animal models and systems for screening compounds to treat and/or prevent such diseases..
08/14/14
20140227711
 Genotoxicity as a biomarker for inflammation patent thumbnailnew patent Genotoxicity as a biomarker for inflammation
The invention provides a method for detection of inflammatory disease in a subject that comprises assaying a test sample of peripheral blood from the subject for a marker of dna damage. An elevated amount of marker present in the test sample compared to control sample is indicative of inflammatory disease activity, including sub-clinical inflammation.
08/14/14
20140227273
 Multi-specific binding molecules targeting aberrant cells patent thumbnailnew patent Multi-specific binding molecules targeting aberrant cells
Described are proteinaceous molecules comprising at least two, preferably three to six, binding domains that bind specifically to at least two different binding sites on aberrant cells. These multi-domain and multi-specific binding molecules are preferably used in selectively modulating biological processes.
08/07/14
20140220021
 Therapeutic agent for autoimmune diseases comprising pd-1 agonist patent thumbnailTherapeutic agent for autoimmune diseases comprising pd-1 agonist
Provided is a prophylactic, symptom progress-suppressive, and/or therapeutic agent for an autoimmune disease. The agent lowers the risk of infections and reduces the burden of administration to patients.
07/31/14
20140215644
 Soluble protein cd5 or cd6 for the treatment of cancer or tumor or for use as an adjuvant patent thumbnailSoluble protein cd5 or cd6 for the treatment of cancer or tumor or for use as an adjuvant
The present invention discloses soluble isoforms of cd5 and cd6, which are scavenger-like lymphocyte receptors, for use in the prophylaxis or therapy of disorders or in therapeutic interventions, which would benefit from an exacerbated immune response to either endogenous or exogenous antigens, resulting from a decrease in lymphocyte subpopulations with regulatory functions and/or increase in lymphocyte subpopulations with effector functions. Special disorders are cell growth disorders, and chronic infections of bacterial, viral, fungal or parasitic origin.
07/31/14
20140213600
 Medicament for treating peripheral neuropathies patent thumbnailMedicament for treating peripheral neuropathies
The invention provides a method for treatment of the diseases in a human by identifying the human as one suffering from a herpes simplex virus (hsv), and then administering to the human the compound anti-hsv agent or a pharmaceutically acceptable salt thereof. The diseases include dermatosis and non-dermatosis, wherein the dermatosis include acnes, impetigo, pyoderma gangrenosum, chilblains and psoriasiform, asteatotic dermatitis, ichthyosis, lichen simplex chronicus (neurodermatitis, prurigo), seborrhoeic dermatitis, rosacea, perioral dermatitis, epidermal cyst, wound ulcer, discoid lupus erythematosus, vitiligo, alopecia, diagnostic criteria of some autoimmune diseases such as systemic lupus erythematosus or diabetic skin complications, wherein the non-dermatosis include glomerulonephritis, arthritis, crohn's disease, ulcerative colitis, myelodysplasia, multiple myeloma, demyelinating disease, parkison's disease, anemia, cytopenia those among the diagnostic criteria..
07/31/14
20140213576
 Novel compound useful for the treatment of degenerative and inflammatory diseases patent thumbnailNovel compound useful for the treatment of degenerative and inflammatory diseases
A novel compound according to formula i, able to inhibit jak as disclosed, this compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic or inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6 or interferons.. .
07/31/14
20140213555
 Compounds and method for treating autoimmune diseases patent thumbnailCompounds and method for treating autoimmune diseases
Wherein x and y independently are o or nr1; each r1 is independently h or c1-c6 alkyl; ring a is aryl; each r2 independently is h, alkyl, alkoxy, amide, cyano, halo, haloalkyl, hydroxyalkyl, heteroalkyl, heterocyclyl, sulfonyl, sulfonamide, or two r2 groups, taken together with the atom or atoms to which they are attached, combine to form a 4-10 membered ring system; p is 0, 1, 2, 3, or 4; r3 and r4 independently are h or c1-c6 alkyl; and r5 is halo, cyano, or c1-c6 alkyl.. .
07/31/14
20140212485
 Inhibitors of bruton's tyrosine kinase patent thumbnailInhibitors of bruton's tyrosine kinase
Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
07/31/14
20140212441
Pharmaceutical composition for inflammatory diseases, allergic diseases and autoimmune diseases
The present invention relates to methods and pharmaceutical compositions for immunosuppression by using the fatty acid derivative represented by formula (i). The present invention further relates to methods and pharmaceutical compositions for treating inflammatory diseases, allergic diseases and autoimmune diseases by using said fatty acid derivative..
07/31/14
20140212383
Suppressor of the endogenous interferon-gamma
The invention relates to suppressors of endogenous human interferon-gamma (inf-γ) applicable in treatment of diseases associated with impaired activity of endogenous ifn-γ. The suppressors of the invention are useful in treating autoimmune diseases and for prevention of graft arteriosclerosis and rejection of organs in allograft transplanted patients.
07/24/14
20140207220
Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism
An implantable medical device is provided for the suppression or prevention of pain, movement disorders, epilepsy, cerebrovascular diseases, autoimmune diseases, sleep disorders, autonomic disorders, abnormal metabolic states, disorders of the muscular system, and neuropsychiatric disorders in a patient. The implantable medical device can be a neurostimulator configured to be implanted on or near a cranial nerve to treat headache or other neurological disorders.
07/24/14
20140206694
Heterocyclic compounds and their uses
Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (sle), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, the present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as acute myeloid leukaemia (aml) myelo-dysplastic syndrome (mds) myelo-proliferative diseases (mpd) chronic myeloid leukemia (cml) t-cell acute lymphoblastic leukaemia (t-all) b-cell acute lymphoblastic leukaemia (b-all) non hodgkins lymphoma (nhl) b-cell lymphoma and solid tumors, such as breast cancer.. .
07/24/14
20140206625
Method of using dopamine reuptake inhibitors and their analogs for treating autoimmune conditions and delaying or preventing autoimmune related pathologic progressions
Dopamine reuptake inhibitors, and their analogs, are disclosed for treating and delaying the progression of autoimmune diseases.. .
07/17/14
20140200245
Inhibitors of c-fms kinase
Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..
07/17/14
20140199379
Compositions having means for targeting at least one antigen to dendritic cells
A composition that can be used as a vaccine containing means for targeting at least one antigen to dendritic cells and as adjuvants a granulocyte macrophage colony stimulating factor and a cpg oligodeoxynucleotide and/or a cpg-like oligodeoxynucleotide. This composition can used to treat cancers, infectious diseases caused by bacterial, viral, fungal, parasitic or protozoan infections, allergies and/or autoimmune diseases..
07/17/14
20140199328
Interferon alpha antibodies and their uses
The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (ifn) alpha subtypes but do not substantially inhibit the biological activity of ifn alpha 21 or the biological activity of either ifn beta or ifn omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided.
07/10/14
20140195216
Computational design of ideotypically modulated pharmacoeffectors for selective cell treatment
In system and method embodiments, an embodiment includes the collection, input, and organization of target nucleotide source or sources; the identification of potential target sequences for ideotypically modulated pharmacoeffectors (imp); the exclusion, prioritization, or deprioritization of target sequences on the basis of undesirable binding for ideotypically modulated pharmacoeffectors (imp); and/or the design of targeting sequences on the basis of reverse complementarity or sequence complementarity. Imps are designed for optimal use in respective applications, including cancers, autoimmune diseases, infectious diseases, cellular diseases, and other applications..
07/10/14
20140194343
Ctrp6 which can be used as therapeutic and prophylactic agent for autoimmune diseases
[solution] a pharmaceutical composition containing ctrp6 for the prevention or treatment of autoimmune disease. Ideally, a pharmaceutical composition for the prevention or treatment of inflammation associated with autoimmune disease, for example, rheumatoid arthritis or type 1 diabetes, is provided..
07/10/14
20140193337
18f-saccharide-folates
The present invention is directed towards new 18f-folate radiopharmaceuticals, wherein the 18f isotope is linked via a prosthetic group, more specifically via a prosthetic group having a saccharide group, such as a cyclic mono- or oligosaccharide, preferably based on a pyranoside or furanoside, which is covalently linked to the glutamate portion of a folate or derivative thereof, a method of their preparation, as well as their use in diagnosis and monitoring of cancer and inflammatory and autoimmune diseases and therapy thereof.. .
07/03/14
20140187565
Inhibitors of bruton's tyrosine kinase
Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
07/03/14
20140187564
Inhibitors of bruton's tyrosine kinase
Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
07/03/14
20140186400
Methods and compositions for treating autoimmune diseases
The invention features methods for increasing or maintaining the number of functional cells of a predetermined type, for example, insulin producing cells of the pancreas, blood cells, spleen cells, brain cells, heart cells, vascular tissue cells, cells of the bile duct, or skin cells, in a mammal (e.g., a human patient) that has injured or damaged cells of the predetermined type.. .
07/03/14
20140186374
Manipulation of regulatory t cell and dc function by targeting neuritin gene using antibodies, agonists and antagonists
We demonstrate herein that neuritin controls the homeostasis of regulatory t cells in an antigen dependent manner. Based on this discovery, we describe herein the application of neuritin as a therapeutic agent to manipulate antigen specific regulatory t cells in various disease settings is described.
06/26/14
20140179703
Concentrated methotrexate solutions
Concentrated methotrexate solutions are described which are suitable for the use of an active substance in the production of a parenterally administered medicament for the treatment of inflammatory autoimmune diseases. The methotrexate is added to a pharmaceutically acceptable solvent at a concentration of more than 25 mg/ml.
06/26/14
20140179662
Pharmaceutically active disubstituted triazine derivatives
The present invention relates to disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said disubstituted triazine derivatives as inhibitors for a protein kinase..
06/26/14
20140178389
Il-1 binding proteins
The disclosure provides binding proteins that specifically bind to il-1α and il-1β. These binding proteins can be organized into dvd-igs.
06/19/14
20140171621
Galectin-immunoglobulin chimeric molecules
Described are galectin-1/ig fusion constructs and methods of use thereof, e.g., in diagnostic and biomedical assays, and as therapeutic agents for the treatment of conditions associated with immune dysfunction, e.g., autoimmune diseases, and cancers.. .
06/19/14
20140171453
Inhibitors of bruton's tyrosine kinase
Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
06/19/14
20140170173
Method of inducing immune tolerance comprising administering carbonic anhydrase i
The purpose of the present invention is to provide a method for treating autoimmune diseases. Disclosed is a method or the like for the treatment of autoimmune diseases, which utilizes an antigen-specific tolerogenic antigen presenting cell.
06/19/14
20140170172
Tat-based tolerogen compositions and methods for making and using same
A tat-based tolerogen composition comprising at least one immunogenic antigen coupled to at least one human immunodeficiency virus (hiv) trans-activator of transcription (tat) molecule wherein the immunogenic antigen can be a foreign or endogenous antigen or fragments thereof. Additionally methods of suppressing organ transplant rejection and methods of treating autoimmune diseases are provided..
06/19/14
20140170067
New ligands for targeting of s1p receptors for in vivo imaging and treatment of diseases
The present invention relates to novel compounds of formulae (i) and (ii) which are useful in the prevention, treatment and diagnosis, in vivo diagnosis of diseases or disorders related to s1p receptors, in particular, in diseases which are connected to the regulatory function of sphingosine-1-phosphate (s1p) and its analogues, such as inflammation, pain, autoimmune diseases and cardiovascular diseases.. .
06/12/14
20140163075
Modulation of the ubiquitin-proteasome system (ups)
The invention relates to the field of 26s proteasome inhibition, activation and modulation and to identify compounds which activate 26s proteasome in live cells and a method of treating autoimmune diseases, cancer, inflammation and neurogenerative disorders by inhibition, activation and modulation of the 26s proteasome.. .
06/12/14
20140163074
Pharmaceutical composition for treating dermatological autoimmune diseases
There is proposed a pharmaceutical composition for treating dermatological autoimmune diseases, comprising a proton pump inhibitor.. .
06/12/14
20140163046
Inhibitors of bruton's tyrosine kinase
Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
06/12/14
20140162999
Pim kinase inhibitors and preparation methods and use in medicinal manufacture thereof
Pim kinase inhibitor compound having a structure as represented by formula i, and isomers, diastereomers, enantiomers, tautomers, and pharmaceutically acceptable salts of the compounds as represented by formula i. The compounds significantly inhibit the pim kinase activity and are used to prepare drugs to treat pim kinase mediated diseases, such as cancers, autoimmune diseases, allergic reactions, or organ transplant rejection.
06/12/14
20140162998
Pim kinase inhibitors and preparation methods and use in medicinal manufacture thereof
A pim kinase inhibitor compound having the structure represented by formula i, and isomers, diastereomers, enantiomers, tautomers, and pharmaceutically acceptable salts thereof. The compounds significantly inhibit pim kinase activity and can be used to prepare drugs for treating pim kinase mediated diseases, such as cancers, autoimmune diseases, allergic reactions, or organ transplant rejection.
06/12/14
20140161812
Immunoregulation in cancer, chronic inflammatory and autoimmune diseases
The present invention primarily relates to a method for analyzing the amount of immunoregulatory integrin binding factors and/or patient endogenous antibodies which are directed against such factors, the factors having the capacity to modulate the immune functions in a. Subject suffering from cancer or inflammatory or autoimmune diseases, by utilizing binding reagents to determine these factors and/or the patient endogenous antibodies which are directed against such factors, whereby the prognosis and/or the therapeutic efficacy of any treatment of a subject suffering from cancer or inflammatory or autoimmune diseases can be determined and/or monitored.
06/05/14
20140155466
Use of aptamers in therapy and/or diagnosis of autoimmune diseases
The present invention is directed to an aptamer comprising or consisting of the nucleic acid sequence of seq id no. 1, seq id no.
06/05/14
20140155405
Concentrated methotrexate solutions
Concentrated methotrexate solutions are described which are suitable for the use of an active substance in the production of a parenterally administered medicament for the treatment of inflammatory autoimmune diseases. The methotrexate is added to a pharmaceutically acceptable solvent at a concentration of more than 25 mg/ml.
06/05/14
20140154277
Pharmaceutical compositions comprising soluble cd137
A method for treating or preventing a t-cell-mediated autoimmune disease is provided herein, the method including administering to a mammal in need thereof a therapeutically effective amount of soluble cd137 or cd137pos regulatory t cells. Also provided are pharmaceutical compositions for treating or preventing t-cell-mediated autoimmune diseases, the pharmaceutical compositions including a therapeutically effective amount of soluble cd137 or cd137pos regulatory t cells and a pharmaceutically-acceptable carrier..
06/05/14
20140154276
Mesenchymal stem cells and uses therefor
Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.. .
06/05/14
20140154242
Immunoglobulin variants and uses thereof
The invention provides humanized and chimeric anti-cd20 antibodies for treatment of cd20 positive malignancies and autoimmune diseases.. .
06/05/14
20140154227
Cell populations having immunoregulatory activity, method for isolation and uses
The present invention provides a population of mesenchymal cells that do not express the cell surface markers cd112 and/or cd155 for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues.. .
05/29/14
20140148448
Inhibitors of c-fms kinase
Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..
05/29/14
20140148394
Compositions and methods for modulating gamma-c-cytokine activity
The various embodiments relate to peptide antagonists of γc-family cytokines, interleukin-2 (il-2), interleukin-4 (il-4), interleukin-7 (il-7), interleukin-9 (il-9), interleukin-15 (il-15), and interleukin-21 (il-21). The γc-cytokines are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (gvhd).
05/29/14
20140147455
Antigen surrogates in autoimmune disease
The present invention provides for the identification of an antigen surrogate to the native antigens for the autoimmune disease pemphigus vulgaris. Ligands are discovered using large random peptoid or cyclic peptoid libraries that are screened against known antibodies to autoimmune diseases.
05/29/14
20140147447
Anti-cxcl13 antibodies and methods of using the same
Compositions and methods are provided for treating diseases associated with cxcl13 expression, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-cxcl13 monoclonal antibodies have been developed to neutralize cxcl13..
05/29/14
20140147382
Immunotherapy of b cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
The invention is directed to a method for treating a treating and diagnosing a b cell-related disease, t cell-related disease or an autoimmune disease in a mammal by concurrently or sequentially administering to the mammal a therapeutic composition that comprises a pharmaceutically acceptable vehicle and at least one conjugated antibody, wherein predosing with a non-radiolabeled antibody is not performed.. .
05/22/14
20140142126
Pyrrolopyrimidine compounds as kinase inhibitors
Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
05/22/14
20140142123
Inhibitors of bruton's tyrosine kinase
Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
05/22/14
20140142099
Purinone derivatives as tyrosine kinase inhibitors
The present disclosure provides compounds and pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular blk, bmx, egfr, her2, her4, itk, tec, btk, and txk and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as autoimmune diseases, cancer and inflammatory diseases. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof..
05/22/14
20140142082
Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor rar-related orphan receptor-gamma (ror-gamma, nr1f3) activity and for the treatment of chronic inflammatory and autoimmune diseases
The invention provides modulators for the orphan nuclear receptor rory and methods for treating rory mediated diseases by administrating these novel rory modulators to a human or a mammal in need thereof. Specifically, the present invention provides pyrrolo sulfonamide compounds of formula (1) and the enantiomers, diastereomers, tautomers, solvates and pharmaceutically acceptable salts thereof..
05/15/14
20140135385
Ryanodine receptor inhibitors for treatment of t-cell mediated disorders
This invention relates to methods of treating t-cell mediated diseases or disorders in human or animal subjects, such as autoimmune diseases and chronic graft versus host disease in humans and animals. In particular, the methods comprise administering to the human or animal patient a pharmaceutical composition comprising a ryanodine receptor inhibitor..
05/15/14
20140135347
Inhibitors of bruton's tyrosine kinase
Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
05/15/14
20140135312
Pyrrolopyrimidine compounds and their uses
The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases.
05/15/14
20140134164
Treatment of multiple sclerosis
The present invention concerns treatment of autoimmune diseases with antagonists which bind to b cell surface markers, such as cd19 or cd20.. .
05/08/14
20140128414
Inhibitors of bruton's tyrosine kinase
Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
05/08/14
20140128413
Inhibitors of bruton's tyrosine kinase
Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
05/08/14
20140128324
Methods and compositions for the treatment of cancer or other diseases
The present invention relates to methods and compositions for the treatment of diseases, including cancer, infectious diseases and autoimmune diseases. The present invention also relates to methods and compositions for improving immune function.
05/08/14
20140128321
Method and use of peptide antagonists of zonulin to prevent or delay the onset of diabetes
A method for preventing or delaying the onset of autoimmune diseases is disclosed.. .
05/08/14
20140127154
Pregnancy hormone combination for treatment of autoimmune diseases
The present invention relates to pregnancy hormone combinations and methods of treatment for autoimmune diseases having at least two hormonal components, a pregnancy hormone (such as estriol), and a gestagen (such as levonorgestrel or norethindrone) thereby providing for the continuous, uninterrupted administration of pregnancy hormones for the treatment for autoimmune disorders, such as multiple sclerosis.. .
05/01/14
20140121204
Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders.
The present invention relates to novel compounds according to formula i that antagonize gpr84, a g-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (ibd), rheumatoid arthritis, vasculitis, lung diseases (e.g. Chronic obstructive pulmonary disease (copd) and lung interstitial diseases (e.g.
05/01/14
20140121201
Regulatory network for th17 specification and uses thereof
Screening assays and methods of using same for screening to identify modulator agents or compounds that affect th17 cell specification are described herein. Pharmaceutical compositions comprising agents or compounds that modulate th17 cell specification are also encompassed.
05/01/14
20140121195
Substituted benzimidazoles and benzopyrazoles as ccr(4) antagonists
Benzimidazole, benzopyrazole and benzotriazole compounds are provided which bind to ccr(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.. .
05/01/14
20140120557
Photocrosslinkable peptide-mhc complexes for antigen-specific t cells and methods of using the same
Methods for labeling and/or detecting a t cell according to specificity of an antigen t cell receptor (tcr) are provided. Also provided are monomeric mhc-peptide complexes and kits for crosslinking to a t cell according to specificity of an antigen t cell receptor (tcr).
05/01/14
20140120552
Sensitive and rapid methods of using chimeric receptors to identify autoimmune disease and assess disease severity
The present invention provides methods and compositions useful in the diagnosis and management of autoimmune diseases. In particular, the present invention provides improved methods and compositions for the diagnosis and management of graves' disease.
05/01/14
20140120111
Treatment of autoimmune disorders and infections using antagonists of sgk1 activity
The present invention provides novel methods for treating th2-mediated immune disorders and enhancing th1-mediated immune responses in a subject comprising administering to the subject, a pharmaceutical composition comprising a serum-glucocorticoid regulated kinase 1 (sgk1) inhibitor and a pharmaceutically acceptable carrier. Methods for treating a wide range of autoimmune diseases are also taught.
05/01/14
20140120109
Human antibodies to human tnf-like ligand 1a (tl1a)
A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human tnf-like ligand 1a (htl1a) is provided. The human anti-htl1a antibodies are useful in treating diseases or disorders associated with tl1a, such as inflammatory diseases or disorders, e.g., inflammatory bowel diseases, including ulcerative colitis and crohn's disease, rheumatoid arthritis, and the like; autoimmune diseases or disorders, such as multiple sclerosis, diabetes, and the like; and allergic reactions, such as asthma and allergic lung inflammation..
05/01/14
20140120080
Method for treating or preventing an inflammatory disease and/or an autoimmune disease
The present invention relates to a method for treating or preventing either one or both of an inflammatory disease and an autoimmune disease in a patient, wherein the method comprises providing a pharmaceutical composition containing a therapeutically effective amount of soluble fcγr; administering said composition to a patient, followed by a safety period of several weeks, followed by a subsequent treatment cycle of at least two weekly administrations, wherein said therapeutically effective amount is effective to treat or prevent said disease in said patient. The present invention also provides a pharmaceutical composition in the form of a multiple-dosage-kit which contains sufficient amounts of administration doses of soluble fcγr for effectively treating or preventing inflammatory diseases and/or autoimmune diseases in a patient..


Popular terms: [SEARCH]

Autoimmune Diseases topics: Immune Diseases, Autoimmune Disease, Autoimmune Diseases, Immune Disease, Autoimmune, Rheumatoid Arthritis, Antibodies, Proliferative, Nucleotide, Antagonist, Infectious Diseases, Inflammatory Disease, Infectious Disease, Infectious, Multiple Sclerosis

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Autoimmune Diseases for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Autoimmune Diseases with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.8511

3902

6 - 0 - 71